Gencellmed Inc.
- Biotech or pharma, therapeutic R&D
Gencellmed has developed a cutting-edge virus engineering platform called SMART (Synthetic & Multi-Antigen Retargeting Technology), designed to create therapeutic viruses that specifically target and destroy cancer cells while sparing normal tissue. These engineered oncolytic viruses recognize and bind only to predefined biomarkers on cancer cells using custom-designed adapters and engineered viral envelope proteins, ensuring highly selective infection and replication.
By combining self-targeting adapters with modified viral glycoproteins (like gH), GCM achieves dual-targeting precision. The viruses replicate exclusively within diseased cells, minimizing systemic side effects. Additionally, the viruses are armed with genes encoding immunostimulatory molecules such as cytokines, enhancing localized immune activation against tumors. This synergistic strategy not only eliminates cancer cells directly but also boosts the body’s own immune response for long-term protection.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}